Namita Sood is a Respiratory physician affiliated with University of California Davis Medical Center. OpenAlex indexes 101 publications with 6,265 citations (h-index 15); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2825 J St, Ste 400
Sacramento, CA 95816
Telephone
916-734-5360Registry record last updated 12 Mar 2024.
Clinical trials
- The Expression and Significance of MiRNA
Sponsor: Megan Ballinger
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
10 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- United Therapeutics CorporationProgram year202532 payments$24,472openpaymentsdata.cms.gov ↗
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20255 payments
- Merck Sharp & Dohme LLCProgram year202512 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
47.5%Endothelin Receptor Antagonist19.3%Ambrisentan74%Opsumit15%Letairis12%Part D<11 patientsLoop diuretic10.2%Furosemide64%Torsemide26%Bumetanide10%Part D<11 patients+ 6 more classes in this area
Cancer & immunology
17.5%Kinase inhibitor12.1%Ofev100%Part D≥43 patientsPyridone4.3%Pirfenidone100%Part D≥16 patients+ 1 more class in this area
Genitourinary & hormones
11.7%Phosphodiesterase 5 Inhibitor11.7%Tadalafil62%Sildenafil Citrate28%Adcirca10%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Prognostic Impact of Quantitative CT Disease Extent and Pattern in Fibrotic Hypersensitivity Pneumonitis
Annals of the American Thoracic Society
2026 - American Lung Association Pulmonary Hypertension Roundtable: Executive Summary
Pulmonary Circulation
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Helen Chew, MD
University of California Davis Medical Center
Marcio Malogolowkin, MD
University of California Davis Medical Center
Glenn Yiu, MD, PhD
University of California Davis Medical Center
Arta Monjazeb, MD, PhD
University of California Davis Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”